HUGE NEWS ON DNAP
SARASOTA, Fla.--(BUSINESS WIRE)--July 27, 2000--DNAPrint genomics
(Pink Sheets:DNAP) announced today that it is one of only five
emerging companies that has been invited to present at the 8th Annual
BioPartnering Europe (BPE) conference held in London October 16-17th.
The conference is been invited to present at the 8th Annual
BioPartnering Europe (BPE) conference held in London October 16-17th.
The conference is the premier European venue for showcasing innovative
biopharmaceutical and diagnostics companies from Europe, North America,
Japan and the rest of the world. The theme of the 8th annual meeting
is "Investing in Electronic R and D: New partnerships arising from the
convergence of chemistry, biology, computing and automation."
Presentation at the conference is by invitation only and Emerging
Company Presentation invitations are prestigious. As an Emerging
Company Presenter, DNAPrint genomics will present a company profile
before a captive audience in the main plenary hall. DNAprint genomics
will present information about its science and technology, partnering
strategy, developmental programs and capabilities, commercialization
plans and product opportunities.
The purpose of the meeting is to bring together less well-known
companies and established biopharmaceutical companies to explore
opportunities for mutually beneficial partnerships and collaborations.
The conference is sponsored by Technology Vision Group LLC,
(www.biopartnering.com/bpe) and will host 100 innovative
biopharmaceutical and diagnostics companies, and several hundred more
established companies. Last years meeting involved 416 companies from
22 different countries.
About DNAPrint genomics
DNAPrint genomics, Inc. will provide practitioners of genomics
research and personalized medicine with a comprehensive system for
disease dissection and patient classification. Health care
professionals and biopharmaceutical scientists will be able to use the
company's system, through a combination of on-site hardware/software
placement and ASP (application-service provider) resources, to draw
highly sophisticated conclusions and associations between genotype
(SNP an haplotype) data and phenotypic traits (such as drug response).
The analytical heart of the system is a collection of sophisticated
algorithms that enable a quantitative and multivariate dissection of
high-density genotype matrices in complex genetic terms for various
human diseases and drug-interaction traits. The system uses a variety
of novel mathematical modeling and programming techniques, which
comprise the bulk of the companies budding intellectual property
portfolio. The company is applying it's informatics platform to
real-world pharmacogenomic study in order to build a portfolio of
pharmacogenomics "solutions". These "solutions" mathematically express
the nature of the genotype-phenotype relationship for a given drug,
and will be used by future DNAprint genomics customers as a template
against which they can screen an unknown. The company has already
filed patent applications for a genetic analysis reagent that confers
considerable advantages for high-throughput DNA sequencing and
genotyping. The company intends to patent the application of its
informatics platform to the field of genomic research and for
personalized medical applications. The company will also patent each
pharmacogenomic and disease "solution" that it generates, as a unique,
predictive and preventative diagnostic or "diagnomic" product..
DNAPrint genomics Inc. was founded by a group of scientists with
research and commercial experience in high-level mathematical
modeling, programming and molecular genetics. For more information
about the company, please visit www.dnaprint.com.
For scientific inquiries please contact: Dr. Tony Frudakis at
(941) 351-4543. All other inquiries please contact: Richard Craig Hall
at (941) 341-0136.
Except for factual statements made herein, the information
contained in this press release consists of forward-looking statements
that involve risks and uncertainties. The Company's actual results
could differ materially from those contained in such statements.
Factors that could cause or contribute to such differences include
unexpected shortages of critical components, rescheduling or
cancellation of customer orders, the timing and market acceptance of
new product introductions by the Company and its competitors, and
general competition and price pressures in the marketplace.
--30--nmb/mi*
CONTACT: For scientific inquiries:
DNAPrint genomics, Inc., Sarasota
Dr. Tony Frudakis, 941/351-4543
or
All other inquiries:
Richard Craig Hall, 941/341-0136
KEYWORD: FLORIDA
INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY HARDWARE SOFTWARE |
